Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up to $11.28

Neumora Therapeutics, Inc. (NASDAQ:NMRA)’s share price gapped up before the market opened on Monday . The stock had previously closed at $11.28, but opened at $11.77. Neumora Therapeutics shares last traded at $11.65, with a volume of 46,912 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. William Blair reissued an “outperform” rating on shares of Neumora Therapeutics in a research note on Friday, April 12th. Mizuho assumed coverage on Neumora Therapeutics in a research report on Monday, July 8th. They set an “outperform” rating and a $20.00 price objective for the company. Needham & Company LLC started coverage on shares of Neumora Therapeutics in a research report on Monday. They issued a “buy” rating and a $23.00 target price for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 price objective on shares of Neumora Therapeutics in a research note on Thursday, March 28th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.33.

Neumora Therapeutics Stock Performance

The company has a fifty day moving average of $10.05 and a two-hundred day moving average of $12.84.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.34). Analysts predict that Neumora Therapeutics, Inc. will post -1.46 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Amalgamated Bank bought a new position in Neumora Therapeutics during the 4th quarter worth $29,000. Tower Research Capital LLC TRC acquired a new position in Neumora Therapeutics in the fourth quarter valued at about $44,000. Strs Ohio acquired a new position in Neumora Therapeutics in the fourth quarter valued at about $54,000. SG Americas Securities LLC bought a new stake in Neumora Therapeutics during the fourth quarter worth about $108,000. Finally, New York State Common Retirement Fund acquired a new stake in Neumora Therapeutics during the fourth quarter worth about $118,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.